Microbot Medical Stock Forecast, Price & News

-0.15 (-1.96 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume153,448 shs
Average Volume75,093 shs
Market Capitalization$53.47 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MBOT News and Ratings via Email

Sign-up to receive the latest news and ratings for Microbot Medical and its competitors with MarketBeat's FREE daily newsletter.

Microbot Medical logo

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 42 issued/allowed patents and 23 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.26 out of 5 stars

Medical Sector

897th out of 2,099 stocks

Biological Products, Except Diagnostic Industry

130th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Microbot Medical (NASDAQ:MBOT) Frequently Asked Questions

Is Microbot Medical a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Microbot Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Microbot Medical stock.
View analyst ratings for Microbot Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Microbot Medical?

Wall Street analysts have given Microbot Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Microbot Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Microbot Medical?

Microbot Medical saw a decline in short interest in May. As of May 28th, there was short interest totaling 309,900 shares, a decline of 13.8% from the May 13th total of 359,400 shares. Based on an average daily trading volume, of 82,000 shares, the days-to-cover ratio is presently 3.8 days. Currently, 5.1% of the shares of the stock are sold short.
View Microbot Medical's Short Interest

When is Microbot Medical's next earnings date?

Microbot Medical is scheduled to release its next quarterly earnings announcement on Friday, June 18th 2021.
View our earnings forecast for Microbot Medical

How were Microbot Medical's earnings last quarter?

Microbot Medical Inc. (NASDAQ:MBOT) issued its earnings results on Tuesday, March, 30th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.03.
View Microbot Medical's earnings history

How has Microbot Medical's stock been impacted by Coronavirus?

Microbot Medical's stock was trading at $6.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MBOT shares have increased by 17.9% and is now trading at $7.52.
View which stocks have been most impacted by COVID-19

When did Microbot Medical's stock split? How did Microbot Medical's stock split work?

Shares of Microbot Medical reverse split on the morning of Monday, May 9th 2016. The 1-12 reverse split was announced on Friday, May 6th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 6th 2016. An investor that had 100 shares of Microbot Medical stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for MBOT?

1 analysts have issued 12-month target prices for Microbot Medical's shares. Their forecasts range from $20.00 to $20.00. On average, they expect Microbot Medical's stock price to reach $20.00 in the next year. This suggests a possible upside of 166.0% from the stock's current price.
View analysts' price targets for Microbot Medical
or view top-rated stocks among Wall Street analysts.

Who are Microbot Medical's key executives?

Microbot Medical's management team includes the following people:
  • Mr. Harel Gadot, Co-Founder, Pres, CEO & Chairman (Age 48, Pay $733.8k)
  • Mr. David Ben Naim CPA, M.B.A., Chief Financial Officer (Age 52, Pay $82.24k)
  • Dr. Eyal Morag M.D., Chief Medical Officer (Age 56, Pay $371.58k)
  • Prof. Moshe Shoham, Co-Founder, Scientific Director & Member of Scientific Advisory Board (Age 69)
  • Dr. Simon Sharon, CTO & Chairman of Scientific Advisory Board (Age 61)
  • Dr. Eric C. Leuthardt, Scientific Director & Member of Scientific Advisory Board

Who are some of Microbot Medical's key competitors?

What other stocks do shareholders of Microbot Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Microbot Medical investors own include TransEnterix (TRXC), Advanced Micro Devices (AMD), Athersys (ATHX), NVIDIA (NVDA), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Pfizer (PFE), Micron Technology (MU) and Sorrento Therapeutics (SRNE).

What is Microbot Medical's stock symbol?

Microbot Medical trades on the NASDAQ under the ticker symbol "MBOT."

Who are Microbot Medical's major shareholders?

Microbot Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.73%), Citadel Advisors LLC (0.23%), Citadel Advisors LLC (0.23%), Millennium Management LLC (0.16%) and Investment Management Associates Inc. ADV (0.14%).
View institutional ownership trends for Microbot Medical

Which major investors are buying Microbot Medical stock?

MBOT stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Citadel Advisors LLC, Millennium Management LLC, Investment Management Associates Inc. ADV, and BlackRock Inc..
View insider buying and selling activity for Microbot Medical
or or view top insider-buying stocks.

How do I buy shares of Microbot Medical?

Shares of MBOT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Microbot Medical's stock price today?

One share of MBOT stock can currently be purchased for approximately $7.52.

How much money does Microbot Medical make?

Microbot Medical has a market capitalization of $53.47 million.

How many employees does Microbot Medical have?

Microbot Medical employs 14 workers across the globe.

What is Microbot Medical's official website?

The official website for Microbot Medical is

Where are Microbot Medical's headquarters?

Microbot Medical is headquartered at 25 RECREATION PARK DRIVE UNIT 108, HINGHAM MA, 02043.

How can I contact Microbot Medical?

Microbot Medical's mailing address is 25 RECREATION PARK DRIVE UNIT 108, HINGHAM MA, 02043. The biotechnology company can be reached via phone at 781-875-3605 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.